Consolidated Statement of Changes in Capital (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year (in shares)	21,605,093
Balance at beginning of year	$ 801,460	$ 669,048	$ 669,048
Net income (loss)	24,803	4,541
Currency translation adjustments	1,093	(459)
Equity compensation - restricted units	(11)	119
Tax withholding related to vesting of restricted units	(333)
Purchases of SPLP common units		(10,418)
Purchases of SPLP common units	(3,248)
Purchases of subsidiary shares from noncontrolling interests		(8,606)
Other, net	$ (61)
Balance at end of period (in shares)	21,667,031		21,605,093
Balance at end of year	$ 819,841	654,225	$ 801,460
Accounting Standards Update [Extensible Enumeration]			Impact of adopting current expected credit loss accounting guidance
Cumulative Effect, Period of Adoption, Adjustment
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	(3,862)
Balance at end of year			$ (3,862)
Total Partners' Capital
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	800,220	663,337	663,337
Net income (loss)	24,846	4,565
Currency translation adjustments	1,093	(459)
Equity compensation - restricted units	(11)	119
Tax withholding related to vesting of restricted units	(333)
Purchases of SPLP common units		(10,418)
Purchases of SPLP common units	(3,248)
Purchases of subsidiary shares from noncontrolling interests		(3,942)
Other, net	(61)
Balance at end of year	818,644	$ 653,202	800,220
Total Partners' Capital | Cumulative Effect, Period of Adoption, Adjustment
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	$ (3,862)
Balance at end of year			$ (3,862)
Common Units
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year (in shares)	39,509,772	37,828,941	37,828,941
Equity compensation - restricted units (in shares)	146,414	(37,315)
Tax withholding related to vesting of restricted units (in shares)	(8,972)
Balance at end of period (in shares)	39,647,214	37,791,626	39,509,772
Treasury Units
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year (in shares)	17,904,679	16,810,932	16,810,932
Balance at beginning of year	$ (309,257)	$ (264,284)	$ (264,284)
Purchases of SPLP common units (in shares)		(268,623)
Purchases of SPLP common units		$ (10,418)
Purchases of SPLP common units (in shares)	(75,504)
Purchases of SPLP common units	$ (3,248)
Balance at end of period (in shares)	17,980,183	17,079,555	17,904,679
Balance at end of year	$ (312,505)	$ (274,702)	$ (309,257)
Partners' Capital
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	952,094	795,140	795,140
Net income (loss)	24,846	4,565
Equity compensation - restricted units	(11)	119
Tax withholding related to vesting of restricted units	(333)
Purchases of SPLP common units		(10,418)
Purchases of SPLP common units	(3,248)
Purchases of subsidiary shares from noncontrolling interests		(3,942)
Other, net	(61)
Balance at end of year	969,425	785,464	952,094
Partners' Capital | Cumulative Effect, Period of Adoption, Adjustment
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	(3,862)
Balance at end of year			(3,862)
Accumulated Other Comprehensive Loss
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	(151,874)	(131,803)	(131,803)
Currency translation adjustments	1,093	(459)
Balance at end of year	(150,781)	(132,262)	(151,874)
Noncontrolling Interests in Consolidated Entities
Increase (Decrease) in Partners' Capital [Roll Forward]
Balance at beginning of year	1,240	5,711	5,711
Net income (loss)	(43)	(24)
Purchases of subsidiary shares from noncontrolling interests		(4,664)
Balance at end of year	$ 1,197	$ 1,023	$ 1,240